M. G. O’Rourke, M. Johnson, C. Lanagan, J. See, J. Yang, J. R. Bell, G. J. Slater, B. M. Kerr, B. Crowe, D. M. Purdie, S. L. Elliott, K. A. Ellem and C. W. Schmidt, “Durable Complete Clinical Responses in a Phase I/II Trial Using an Autologous Melanoma Cell/Dendritic Cell Vaccine,” Cancer Immunology, Immunotherapy, Vol. 52, No. 6, 2003, pp. 387-395.

has been cited by the following article:

• TITLE: Melanoma Immunotherapy: Overcoming Obstacles to Augment Anti-Tumor Immune Responses

  AUTHORS: Kristian M. Hargadon

  KEYWORDS: Melanoma; Tumor Immunotherapy; Dendritic Cell; Tumor Antigen; T Cell; Vaccine; Adoptive Transfer

  JOURNAL NAME: Journal of Cosmetics, Dermatological Sciences and Applications, Vol.3 No.2A, June 20, 2013

  ABSTRACT: Melanoma is the most aggressive form of skin cancer and accounts for the vast majority of skin cancer-related deaths. Its ability to metastasize quickly, often before diagnosis, makes this cancer difficult to treat with traditional therapies. The identification of anti-melanoma immune responses in patients and the discovery of tumor antigens targeted by these immune responses have paved the way for immunotherapy as a novel approach to treating this cancer. In this review, the major immunotherapies targeting these melanoma tumor antigens are discussed. The advantages and limitations of peptide-, protein-, and gene-based vaccination maneuvers and adoptive cell transfer therapies are emphasized. Recent insights into melanoma immune evasion strategies are also highlighted, with particular focus on how our increasing knowledge of tumor/immune cell interactions is driving the development of novel immunotherapeutic strategies for the treatment of melanoma.